Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notice:
Notice of Multiple Institutes' Participation in PAR-13-239 Native American Research Centers for Health (NARCH) (S06)
- The NHLBI, along with other NIH Institutes, has joined the funding opportunity announcement PAR-13-239, entitled “Native American Research Centers for Health (NARCH) (S06)”.
Notice of Correction to RFA-HL-14-014 Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network (U01)
- On May 15, 2013, the NHLBI issued Funding Opportunity Announcement (FOA) RFA-HL-14-014 "Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network (U01)". This Notice corrects the allowable number of satellite recruiting sites.
Notice Providing Additional Information for Applicants to PAR-13-231 Phenotyping Embryonic Lethal Knockout Mice (R01)
- The purpose of this Notice is to provide additional information for applicants interested in responding to PAR-13-231 which encourages R01 applications to phenotype embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member.
Request for Information:
Request for Information (RFI): Input on Administration of the NIH-Industry Pilot Program Discovering
- The goal of this Request for Information (RFI) is to collect feedback from the biomedical research community, pharmaceutical companies, and other members of the public about the “NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules” initiative and the application process. NCATS is interested in feedback from researchers and institutions that submitted an application, considered submitting an application but did not, and/or would be interested in submitting an application in the future. NCATS is also interested in feedback from existing and potential pharmaceutical partners.